Optiscan Imaging has completed the beta phase for its cloud-connected telepathology platform, developed in partnership with Prolucid Technologies.
The platform, which integrates Optiscan’s confocal imaging technology, enables pathologists and clinicians to work together in real time, improving decision-making and patient outcomes, the firm said in an ASX announcement.
By leveraging Optiscan’s MedTech expertise, the telepathology system provides secure device-to-cloud connectivity and a dedicated web portal.
Dr Camile Farah, CEO and managing director of Optiscan, expressed enthusiasm about the progress: “We are thrilled with the outcomes from the beta phase testing of our telepathology platform, which leverages Optiscan’s confocal imaging technology to transform digital pathology. This key stage of the platform’s development journey would not have been possible without the efforts of Prolucid Technologies, our partner in this exciting project.”
The platform captures real-time confocal images at the patient’s side, which are then transmitted to the cloud.
Remote pathologists can join the imaging session on a computer terminal, view and flag images, and communicate observations directly with the clinician performing the imaging, all in real time.
Offline review and annotation of images are also supported, with detailed report generation planned for future versions.
Dr Farah further elaborated, “This achievement makes the platform a potential game changer for telehealth consultations for patients who live outside of capital city areas. In the past, regional, rural, and remote health facilities have lacked the dedicated pathology expertise, limiting collaboration and immediate decision-making between clinicians and pathologists.”
“Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting healthcare professionals. Our telepathology-enabled imaging solutions democratise pathology services and high-quality patient care.”
During the beta phase, Optiscan demonstrated key functionalities, including device registration, authentication, and secure cloud connectivity.
The platform now allows real-time image streaming and post-session review, with proof of concept for image annotation and session data comparison workflows.
Dr Farah concluded, “With the successful beta testing phase complete, we have already ramped up efforts to create a commercial version of our telepathology platform and now look forward to its implementation in clinical settings.”
“Our aim is to initially implement a minimal viable telepathology platform, with further enhancements and features to be developed in subsequent phases.”
